Cargando…
Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces a big challenge due to heterogeneity of tumor, and therapeutic response is complicated by possible immune-related adverse events (irAEs). Therefore, it is critical t...
Autores principales: | Xing, Xiaoqing, Zhao, Qing, Zhou, Jinyun, Zhou, Rui, Liu, Yu, Qin, Xiyi, Zhang, Mingrong, Zhong, Yan, Wang, Jing, Tian, Mei, Zhang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119238/ https://www.ncbi.nlm.nih.gov/pubmed/36622406 http://dx.doi.org/10.1007/s00259-022-06084-1 |
Ejemplares similares
-
Positron emission tomography molecular imaging‐based cancer phenotyping
por: Jin, Chentao, et al.
Publicado: (2022) -
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
por: Bauckneht, Matteo, et al.
Publicado: (2017) -
Positron emission tomography in the COVID-19 pandemic era
por: Jin, Chentao, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography
por: Usmani, Sharjeel, et al.
Publicado: (2019) -
Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis
por: Qualls, David, et al.
Publicado: (2019)